RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX... RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. 詳細を表示
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering...
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.3501 | -20.9640718563 | 1.67 | 1.779 | 1.28 | 1079709 | 1.62001036 | CS |
4 | 0.3201 | 32.0164032807 | 0.9998 | 2.32 | 0.78925 | 10136168 | 1.72008913 | CS |
12 | -0.3801 | -22.3588235294 | 1.7 | 3.32 | 0.78925 | 3575965 | 1.71000541 | CS |
26 | -1.8901 | -58.8816199377 | 3.21 | 3.825 | 0.78925 | 1735826 | 1.78149333 | CS |
52 | -23.4801 | -94.6778225806 | 24.8 | 27.35 | 0.78925 | 1379683 | 4.39024845 | CS |
156 | -37.0201 | -96.557381325 | 38.34 | 38.34 | 0.78925 | 698701 | 9.81257659 | CS |
260 | -26.4801 | -95.2521582734 | 27.8 | 51.2095 | 0.78925 | 540597 | 14.58298164 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約